ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW 253,500
-500 (-0.20%)
Sep 18, 2026, 3:30 PM KST
ALTEOGEN Revenue
ALTEOGEN had revenue of 68.89B KRW in the quarter ending June 30, 2026, with 269.55% growth. This brings the company's revenue in the last twelve months to 254.01B, up 60.71% year-over-year. In the year 2025, ALTEOGEN had annual revenue of 215.86B with 109.87% growth.
Revenue (ttm)
254.01B
Revenue Growth
+60.71%
P/S Ratio
69.49
Revenue / Employee
1.40B
Employees
181
Market Cap
17.65T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 215.86B | 113.00B | 109.87% |
| Dec 31, 2024 | 102.85B | 6.33B | 6.56% |
| Dec 31, 2023 | 96.52B | 67.72B | 235.08% |
| Dec 31, 2022 | 28.81B | -9.94B | -25.65% |
| Dec 31, 2021 | 38.75B | -3.68B | -8.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 861.34B |
| SK bioscience | 659.27B |
| LigaChem Biosciences | 98.78B |
| HLB Co., Ltd. | 97.47B |
| ABL Bio | 34.28B |
ALTEOGEN News
- 16 days ago - Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen - Nasdaq
- 16 days ago - Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology - Reuters
- 4 months ago - ALTEOGEN Q1 Net Income Declines - Nasdaq
- 5 months ago - Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics - Nasdaq
- 6 months ago - ALTEOGEN Annual report: Q4 2025 - Filings
- 10 months ago - ALTEOGEN Quarterly report: Q3 2025 - Filings
- 12 months ago - FDA Clears Merck's One-Minute Cancer Shot - Benzinga